Douglas A. Hamilton

Mr. Douglas A. Hamilton is a Principal at New Biology Ventures LLC.
Previously, he was the Chief Financial Officer at Javelin Pharmaceuticals Inc., (Formerly Intrac Inc.) from March 1999 to May 1, 2006 and served as Chief Operating Officer from December 2004 to February 2006 and also served as Chief Accounting Officer and Treasurer.
He is a Founder at Intrac Inc. and served as its Secretary.
He was the Chief Operating Officer at IDDS (Innovative Drug Delivery Systems ...
Inc.) since April 2001 and Chief Financial Officer since March 1999.
Previously, he served as Chief Financial Officer and Project Manager of Trisenox(R) at PolaRx BioPharmaceuticals.
From March 1999 to August 2002, he also concurrently served as Director, Business Development at Paramount Capital Investments, LLC.
From October 1997 to March 1999, he served as Project Manager at Zithromax(R) and Vfend(R) in addition to being a member of the Strategic Asset Management (SAM) task force in Central Research at Pfizer, Inc. From August 1993 to October 1997.
Mr. Hamilton was a Project Manager at Amgen Inc. for EPOGEN(R), Aransep(R) and STEMGEN(R), among other products, and assumed responsibility for developing and leading a research and development portfolio management system.
He has also served in various capacities at other biopharmaceutical companies including sales and marketing at Pharmacia, business development at NPS Allelix Biopharmaceuticals, Inc. and research at Pasteur Merieux Connaught.
Mr. Hamilton holds a M.B.A. from the Richard Ivey School of Business and a B.S.
in Molecular Biology and Molecular Genetics from the Department of Medical Genetics at the University of Toronto.